Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.

Fediuk DJ, Matschke K, Liang Y, Pelletier KB, Wei H, Shi H, Bass A, Hickman A, Terra SG, Zhou S, Krishna R, Sahasrabudhe V.

Clin Pharmacol Drug Dev. 2019 Jun 20. doi: 10.1002/cpdd.722. [Epub ahead of print]

PMID:
31219248
2.

Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.

Dawra VK, Liang Y, Wei H, Pelletier K, Shi H, Hickman A, Bass A, Terra SG, Zhou S, Krishna R, Sahasrabudhe V.

Clin Pharmacol Drug Dev. 2019 Jun 17. doi: 10.1002/cpdd.703. [Epub ahead of print]

PMID:
31207178
3.

Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies.

Liu J, Tarasenko L, Terra SG, Huyck S, Wu L, Pong A, Calle RA, Gallo S, Darekar A, Mancuso JP.

Diab Vasc Dis Res. 2019 Sep;16(5):415-423. doi: 10.1177/1479164119842513. Epub 2019 May 13.

PMID:
31081371
4.

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.

Liu J, Pong A, Gallo S, Darekar A, Terra SG.

Cardiovasc Diabetol. 2019 May 7;18(1):59. doi: 10.1186/s12933-019-0856-7.

5.

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.

Ji L, Liu Y, Miao H, Xie Y, Yang M, Wang W, Mu Y, Yan P, Pan S, Lauring B, Liu S, Huyck S, Qiu Y, Terra SG.

Diabetes Obes Metab. 2019 Jun;21(6):1474-1482. doi: 10.1111/dom.13681. Epub 2019 Apr 5.

PMID:
30830724
6.

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.

Dawra VK, Liang Y, Shi H, Bass A, Hickman A, Terra SG, Zhou S, Cutler D, Sahasrabudhe V.

Int J Clin Pharmacol Ther. 2019 Apr;57(4):207-216. doi: 10.5414/CP203343.

7.

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.

Hollander P, Hill J, Johnson J, Wei Jiang Z, Golm G, Huyck S, Terra SG, Mancuso JP, Engel SS, Lauring B, Liu J.

Curr Med Res Opin. 2019 Aug;35(8):1335-1343. doi: 10.1080/03007995.2019.1583450. Epub 2019 Mar 25.

PMID:
30760125
8.

Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.

Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, Lauring B, Terra SG.

Diabetes Obes Metab. 2019 Jan 7. doi: 10.1111/dom.13631. [Epub ahead of print]

9.

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin.

Sahasrabudhe V, Fediuk DJ, Matschke K, Shi H, Liang Y, Hickman A, Bass A, Terra SG, Zhou S, Krishna R, Dawra VK.

Clin Pharmacol Drug Dev. 2019 Jul;8(5):619-627. doi: 10.1002/cpdd.629. Epub 2018 Nov 14.

10.

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG; VERTIS-CV Investigators.

Am Heart J. 2018 Dec;206:11-23. doi: 10.1016/j.ahj.2018.08.016. Epub 2018 Sep 5.

11.

Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.

Sahasrabudhe V, Terra SG, Hickman A, Saur D, Raje S, Shi H, Matschke K, Zhou S, Cutler DL.

Clin Ther. 2018 Oct;40(10):1701-1710. doi: 10.1016/j.clinthera.2018.06.015. Epub 2018 Sep 14.

PMID:
30224193
12.

Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.

Dawra VK, Sahasrabudhe V, Liang Y, Matschke K, Shi H, Hickman A, Saur D, Terra SG, Cutler DL.

Clin Ther. 2018 Sep;40(9):1538-1547. doi: 10.1016/j.clinthera.2018.07.014. Epub 2018 Aug 28.

PMID:
30170758
13.

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.

Dawra VK, Cutler DL, Zhou S, Krishna R, Shi H, Liang Y, Alvey C, Hickman A, Saur D, Terra SG, Sahasrabudhe V.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):314-325. doi: 10.1002/cpdd.472. Epub 2018 May 22.

14.

Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.

Raje S, Callegari E, Sahasrabudhe V, Vaz A, Shi H, Fluhler E, Woolf EJ, Schildknegt K, Matschke K, Alvey C, Zhou S, Papadopoulos D, Fountaine R, Saur D, Terra SG, Stevens L, Gaunt D, Cutler DL.

Clin Transl Sci. 2018 Jul;11(4):405-411. doi: 10.1111/cts.12549. Epub 2018 Mar 25.

15.

Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.

Aronson R, Frias J, Goldman A, Darekar A, Lauring B, Terra SG.

Diabetes Obes Metab. 2018 Jun;20(6):1453-1460. doi: 10.1111/dom.13251. Epub 2018 Feb 23.

16.

A Phase 1, Randomized, Placebo- and Active-Controlled Crossover Study to Determine the Effect of Single-Dose Ertugliflozin on QTc Interval in Healthy Volunteers.

Sahasrabudhe V, Saur D, Matschke K, Terra SG, Hickman A, Huyghe I, Shi H, Cutler DL.

Clin Pharmacol Drug Dev. 2018 Jun;7(5):513-523. doi: 10.1002/cpdd.421. Epub 2018 Jan 18.

PMID:
29346837
17.

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.

Miller S, Krumins T, Zhou H, Huyck S, Johnson J, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B.

Diabetes Ther. 2018 Feb;9(1):253-268. doi: 10.1007/s13300-017-0358-0. Epub 2018 Jan 8.

18.

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.

Hollander P, Liu J, Hill J, Johnson J, Jiang ZW, Golm G, Huyck S, Terra SG, Mancuso JP, Engel SS, Lauring B.

Diabetes Ther. 2018 Feb;9(1):193-207. doi: 10.1007/s13300-017-0354-4. Epub 2017 Dec 27.

19.

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.

Pratley RE, Eldor R, Raji A, Golm G, Huyck SB, Qiu Y, Sunga S, Johnson J, Terra SG, Mancuso JP, Engel SS, Lauring B.

Diabetes Obes Metab. 2018 May;20(5):1111-1120. doi: 10.1111/dom.13194. Epub 2018 Jan 25.

20.

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.

Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP, Jiang ZW, Golm G, Engel SS, Lauring B.

Diabetes Ther. 2018 Feb;9(1):49-66. doi: 10.1007/s13300-017-0337-5. Epub 2017 Nov 20.

21.

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.

Dagogo-Jack S, Liu J, Eldor R, Amorin G, Johnson J, Hille D, Liao Y, Huyck S, Golm G, Terra SG, Mancuso JP, Engel SS, Lauring B.

Diabetes Obes Metab. 2018 Mar;20(3):530-540. doi: 10.1111/dom.13116. Epub 2017 Oct 23.

22.

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).

Rosenstock J, Frias J, Páll D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, Terra SG.

Diabetes Obes Metab. 2018 Mar;20(3):520-529. doi: 10.1111/dom.13103. Epub 2017 Oct 2. Erratum in: Diabetes Obes Metab. 2018 Nov;20(11):2708.

PMID:
28857451
23.

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.

Sahasrabudhe V, Terra SG, Hickman A, Saur D, Shi H, O'Gorman M, Zhou Z, Cutler DL.

J Clin Pharmacol. 2017 Nov;57(11):1432-1443. doi: 10.1002/jcph.955. Epub 2017 Jul 13.

24.

Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome.

Dong JQ, Gosset JR, Fahmi OA, Lin Z, Chabot JR, Terra SG, Le V, Chidsey K, Nouri P, Kim A, Buckbinder L, Kalgutkar AS.

Drug Metab Dispos. 2017 May;45(5):501-511. doi: 10.1124/dmd.116.074476. Epub 2017 Mar 2.

PMID:
28254951
25.

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.

Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, Golm G, Johnson J, Saur D, Lauring B, Dagogo-Jack S.

Diabetes Obes Metab. 2017 May;19(5):721-728. doi: 10.1111/dom.12888. Epub 2017 Feb 22.

PMID:
28116776
26.

Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans.

Dong JQ, Varma MV, Wolford A, Ryder T, Di L, Feng B, Terra SG, Sagawa K, Kalgutkar AS.

Drug Metab Dispos. 2016 Feb;44(2):209-19. doi: 10.1124/dmd.115.067868. Epub 2015 Nov 25.

PMID:
26608081
27.

Type 2 Diabetes: Progress Made but Still a Long Road to Travel to Reduce Disease Burden.

Terra SG, Vincent J.

Clin Pharmacol Ther. 2015 Aug;98(2):108-11. doi: 10.1002/cpt.154. No abstract available.

PMID:
26013760
28.

Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha.

Kalgutkar AS, Chen D, Varma MV, Feng B, Terra SG, Scialis RJ, Rotter CJ, Frederick KS, West MA, Goosen TC, Gosset JR, Walsky RL, Francone OL.

Xenobiotica. 2013 Nov;43(11):963-72. doi: 10.3109/00498254.2013.791004. Epub 2013 Apr 30.

PMID:
23631744
29.

A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*.

Terra SG, Somayaji V, Schwartz S, Lewin AJ, Teeter JG, Dai H, Nguyen TT, Calle RA.

Exp Clin Endocrinol Diabetes. 2011 Jul;119(7):401-7. doi: 10.1055/s-0031-1273737. Epub 2011 Apr 6.

PMID:
21472661
30.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.

Rosenstock J, Lewin AJ, Norwood P, Somayaji V, Nguyen TT, Teeter JG, Johnson SL, Dai H, Terra SG.

Diabet Med. 2011 Apr;28(4):464-9. doi: 10.1111/j.1464-5491.2010.03181.x.

PMID:
21392067
31.

The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency.

Dai H, Johnson SL, Terra SG, Marbury TC, Smith WB, Alcorn H, Boyd RA, Wang R, Nguyen TT.

Br J Clin Pharmacol. 2011 Jul;72(1):85-91. doi: 10.1111/j.1365-2125.2011.03954.x.

32.
33.

Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease.

Konstantino Y, Nguyen TT, Wolk R, Aiello RJ, Terra SG, Fryburg DA.

Biomarkers. 2009 Mar;14(2):118-29. doi: 10.1080/13547500902765140.

PMID:
19330590
34.

Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.

Terra SG, Francone OL, Contant CF, Gao X, Lewin AJ, Nguyen TT.

Am J Cardiol. 2008 Aug 15;102(4):434-9. doi: 10.1016/j.amjcard.2008.03.076. Epub 2008 May 22.

PMID:
18678301
35.

Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography.

Aquilante CL, Yarandi HN, Cavallari LH, Andrisin TE, Terra SG, Lewis JF, Hamilton KK, Johnson JA.

Pharmacogenomics J. 2008 Dec;8(6):408-15. doi: 10.1038/sj.tpj.6500490. Epub 2008 Feb 5.

PMID:
18253135
36.

Non-traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?

Konstantino Y, Wolk R, Terra SG, Nguyen TT, Fryburg DA.

Acute Card Care. 2007;9(4):197-206. Review.

PMID:
17924231
37.

Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure.

Lobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF, Schofield RS, Hamilton KK, Herbert Patterson J, Adams KF Jr, Hill JA, Aranda JM Jr, Johnson JA.

Pharmacogenet Genomics. 2007 Apr;17(4):277-82.

PMID:
17496726
38.

Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure.

Aquilante CL, Terra SG, Schofield RS, Pauly DF, Hatton PS, Binkley PF, Johnson JA.

J Card Fail. 2006 Apr;12(3):171-6.

PMID:
16624680
39.

Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study.

Terra SG, McGorray SP, Wu R, McNamara DM, Cavallari LH, Walker JR, Wallace MR, Johnson BD, Bairey Merz CN, Sopko G, Pepine CJ, Johnson JA.

Int J Obes (Lond). 2005 Jul;29(7):746-54.

PMID:
15917856
40.

Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy.

Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hill JA, Aranda JM, Yarandi HN, Johnson JA.

Pharmacogenet Genomics. 2005 Apr;15(4):227-34.

PMID:
15864115
41.

beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.

Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hamilton KK, Aranda JM, Hill JA, Yarandi HN, Walker JR, Phillips MS, Gelfand CA, Johnson JA.

Clin Pharmacol Ther. 2005 Mar;77(3):127-37.

PMID:
15735607
42.

Evaluation of methods for improving precision of blood pressure measurements in phase I clinical trials.

Terra SG, Blum RA, Wei GC, Lew RA, Digenio AG, Rajman I, Kazierad DJ.

J Clin Pharmacol. 2004 May;44(5):457-63.

PMID:
15102865
43.

Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.

Terra SG, Johnson JA.

Am J Cardiovasc Drugs. 2002;2(5):287-96. Review.

PMID:
14727958
44.

Cardiology patient page. Angiotensin receptor blockers.

Terra SG.

Circulation. 2003 Jun 24;107(24):e215-6. No abstract available.

PMID:
12821593
45.

Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics.

Johnson JA, Terra SG.

Pharm Res. 2002 Dec;19(12):1779-87. Review.

PMID:
12523655
46.

Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management.

Humma LM, Terra SG.

Am J Health Syst Pharm. 2002 Jul 1;59(13):1241-52. Review.

PMID:
12116890
47.

Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia.

Humma LM, Puckett BJ, Richardson HE, Terra SG, Andrisin TE, Lejeune BL, Wallace MR, Lewis JF, McNamara DM, Picoult-Newberg L, Pepine CJ, Johnson JA.

Am J Cardiol. 2001 Nov 1;88(9):1034-7. No abstract available.

PMID:
11704005
48.

Therapeutic range of digoxin's efficacy in heart failure: what is the evidence?

Terra SG, Washam JB, Dunham GD, Gattis WA.

Pharmacotherapy. 1999 Oct;19(10):1123-6. Review.

PMID:
10512061
49.

Opioid antagonists in the treatment of pruritus from cholestatic liver disease.

Terra SG, Tsunoda SM.

Ann Pharmacother. 1998 Nov;32(11):1228-30. Review.

PMID:
9825091
50.

Comment: troglitazone drug interactions.

Terra SG, Washam JB, May DB.

Ann Pharmacother. 1998 Oct;32(10):1111. No abstract available.

PMID:
9793611

Supplemental Content

Loading ...
Support Center